BREAKING
Nucor Jumps 5.5% After UBS Downgrades to Neutral 1 hour ago LGI Homes Edges Past Q1 2026 Estimates, Posts $0.24 EPS, Revenue Down 9% 2 hours ago Molina Healthcare Jumps 5.7% After Wells Fargo Maintains Equal-Weight 2 hours ago COPT Defense Properties Crushes Q1 2026 Profit Estimates 2 hours ago Cincinnati Financial Delivers 12% Revenue Growth in Q1 2026 2 hours ago Armstrong World Industries Falls Short of Q1 2026 Profit Forecast at $1.69 EPS 2 hours ago Franklin Resources Releases Q2 2026 Financial Results 3 hours ago JetBlue Airways Reports 20.8% Wider Q1 2026 Loss at -$0.87/Share 3 hours ago NexPoint Residential Trust Q1 2026 EPS Tops Expectations 3 hours ago Down 19.6%: Purple Innovation Slides After Q1 2026 Widening Loss 3 hours ago Nucor Jumps 5.5% After UBS Downgrades to Neutral 1 hour ago LGI Homes Edges Past Q1 2026 Estimates, Posts $0.24 EPS, Revenue Down 9% 2 hours ago Molina Healthcare Jumps 5.7% After Wells Fargo Maintains Equal-Weight 2 hours ago COPT Defense Properties Crushes Q1 2026 Profit Estimates 2 hours ago Cincinnati Financial Delivers 12% Revenue Growth in Q1 2026 2 hours ago Armstrong World Industries Falls Short of Q1 2026 Profit Forecast at $1.69 EPS 2 hours ago Franklin Resources Releases Q2 2026 Financial Results 3 hours ago JetBlue Airways Reports 20.8% Wider Q1 2026 Loss at -$0.87/Share 3 hours ago NexPoint Residential Trust Q1 2026 EPS Tops Expectations 3 hours ago Down 19.6%: Purple Innovation Slides After Q1 2026 Widening Loss 3 hours ago
ADVERTISEMENT
MRK

Merck & Co., Inc.

$MRK NYSE Apr 28, 2026 All Day FY 2026

Investor Toolbox

Listen to Call

Recording not yet available.

Read Transcript

Transcript not yet available.

View Infographic

Infographic not yet available.

Earnings History

View past quarters and earnings trends.

View History

MRK Coverage

Event Merck & Co., Inc. (MRK) Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. Apr 24, 2026 Event Merck & Co., Inc. (MRK) FDA Approves Merck’s Once-Daily IDVYNSO (doravirine/islatravir) Apr 21, 2026 Event Merck & Co., Inc. (MRK) FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer Apr 20, 2026 Transcript Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript Feb 4, 2026 Transcript Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Key highlights from Merck’s (MRK) Q3 2025 earnings results Oct 30, 2025 News Infographic: How Merck (MRK) performed in Q3 2024 Oct 31, 2024